Patents by Inventor Farhad Ravandi

Farhad Ravandi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of specifically engineered enzymes to enhance the efficacy of prodrugs
    Patent number: 7858745
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: December 28, 2010
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Use of specifically engineered enzymes to enhance the efficacy of prodrugs
    Patent number: 7419811
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: September 2, 2008
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Use of Specifically Engineered Enzymes to Enhance the Efficacy of Prodrugs
    Publication number: 20070258968
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Application
    Filed: June 8, 2007
    Publication date: November 8, 2007
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi
  • Use of specifically engineered enzymes to enhance the efficacy of prodrugs
    Publication number: 20050008648
    Abstract: The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with enhanced activity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activity. Furthermore, the invention provides antibody-conjugated enzymes that can be specifically delivered to leukemic blast cells in vivo or ex vivo.
    Type: Application
    Filed: March 1, 2004
    Publication date: January 13, 2005
    Inventors: Arnon Lavie, Manfred Konrad, Farhad Ravandi